Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 /
神经信号通路
膜转运蛋白
/ Calcium Channel / Ethosuximide/乙琥胺

Ethosuximide/乙琥胺 {[allProObj[0].p_purity_real_show]}

货号：A320514 同义名： CI-366; Zarontin

Ethosuximide is used to treat absence seizures.

Ethosuximide/乙琥胺 化学结构 CAS号：77-67-8
Ethosuximide/乙琥胺 化学结构
CAS号：77-67-8
Ethosuximide/乙琥胺 3D分子结构
CAS号：77-67-8
Ethosuximide/乙琥胺 化学结构 CAS号：77-67-8
Ethosuximide/乙琥胺 3D分子结构 CAS号：77-67-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Ethosuximide/乙琥胺 纯度/质量文件 产品仅供科研

货号：A320514 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

更多 >
产品名称 Ca2+ channel-like protein ↓ Calcium Channel ↓ Cav 2.2 ↓ 其他靶点 纯度
CDC25B-IN-2 ✔ Akt 99%+
Clevidipine ✔ 97%
Verapamil HCl ✔ 99%
Amlodipine ✔ 99%
Amlodipine maleate ✔ 98%
(+)-cis-Diltiazem HCl ✔ 99%
Zegocractin ++

Orai1/STIM1-mediated Ca2+ currents, IC50: 120 nM

 		99%+
Tanshinone IIA sulfonate sodium ✔ 98%
Ulixacaltamide ++

hCaV3.1, IC50: 50 nM

hCaV3.2, IC50: 110 nM

 		99%+
Dronedarone HCl ✔ 95%
Nitrendipine +

Calcium channel, IC50: 95 nM

 		98%
Efonidipine HCl monoethanolate ✔ 98%
Cinnarizine ✔ 98%
SEA0400 ++

NCX, IC50: 33 nM

 		ROS,ERK,p38 MAPK 99%+
Fasudil HCl ✔ PKA,Rho 98%
ML-9 ✔ Akt,MLCK 99%+
Flunarizine 2HCl +

Calcium channel, Ki: 68 nM

 		95%
Lomerizine 2HCl ✔ 98%
Efonidipine ✔ 98%
Levamlodipine ✔ 98%
Nisoldipine ++

L-type Cav1.2, IC50: 10 nM

 		97%
Isradipine ✔ 98%
Lacidipine ✔ 98%
Lercanidipine ✔ 99%
Loureirin B ✔ Potassium Channel 99%+
Tetracaine HCl ✔ 98%
Manidipine +++

Calcium channel, IC50: 2.6 nM

 		99%
Manidipine Dihydrochlorid +++

Calcium channel, IC50: 2.6 nM

 		98%
Nicardipine ✔ 99%
Wilforgine ✔ 98+%
Econazole ✔ 99%+
Ginsenoside Rd ✔ NF-κB 98%
Fendiline HCl ✔ 98+%
Mesaconitine ✔ 98%
Tetrandrine ✔ 95%
Nifedipine ✔ 95%
Nilvadipine ++++

Calcium channel, IC50: 0.03 nM

 		98%
Barnidipine ++++

[3H]nitrendipine, Ki: 0.21 nM

 		95+%
Azelnidipine ✔ 97%
Levetiracetam ✔ 98%
Nimodipine ✔ 95%
Benidipine HCl ✔ 98%
Pinaverium bromide ✔ 98%
Pranidipine ✔ 99%
NP118809 +

N-type Ca2+ channel, IC50: 0.11 μM

L-type calcium channel, IC50: 12.2 μM

 		98%
Amlodipine Besylate +++

Calcium channel, IC50: 1.9 nM

 		97%
Cilnidipine ✔ 99%
Cinepazide Maleate ✔ 99% (HPLC)
Terfenadine ✔ 98%
YM-58483 ✔ 99%+
Ranolazine ✔ 98%
Praeruptorin A ✔ p38 MAPK,Akt 98%
Ranolazine 2HCl ✔ 98%
Felodipine ++++

L-type calcium channel, IC50: 0.15 nM

 		98%
PD173212 +++

N-type Ca2+ channel, IC50: 36 nM

 		98%
Levamlodipine besylate ✔ 97%
Carboxyamidotriazole Orotate ✔ 98%
IGS-1.76 ✔ 98+%
WH-4-023 ++++

Cav 2.2, IC50: 0.001 μM

 		++++

Cav 2.2, IC50: 0.001 μM

 		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Ethosuximide/乙琥胺 生物活性

描述 Ethosuximide, 2-ethyl-2-methylsuccinimide, has been used extensively for "petit mal" seizures. Commonly observed side effects of ethosuximide are dose dependent and involve the gastrointestinal tract and central nervous system. The spontaneous pacemaker oscillatory activity of thalamocortical circuitry involves low threshold T-type Ca2+ currents in the thalamus, and ethosuximide is presumed to reduce these low threshold T-type Ca2+ currents in thalamic neurons. Ethosuximide also decreases the persistent Na+ and Ca2+ -activated K+ currents in thalamic and layer V cortical pyramidal neurons[3]. Ethosuximide and valproic acid are more effective than lamotrigine in the treatment of childhood absence epilepsy. Ethosuximide is associated with fewer adverse attentional effects[4]. Concentrations of 2 μM or more of Ethosuximide not only are found to be less effective than 1 μM concentration of Ethosuximide, but also induce cell toxicity. The number and percentage of tubulin β-III immunopositive neurons were increased after 6 days treatment with ethosuximide. Ethosuximide may compensate damage caused by seizure attacks and possibly other neuronal loss disorders[5]. Ethosuximide given with drinking water (300 mg/kg/day) over 45 days slightly reduced proneness to audiogenic epilepsy and increased locomotor activity of the animals at the periphery of the open field[6].

Ethosuximide/乙琥胺 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02205931 Epilepsy Phase 4 Recruiting June 2019 United Kingdom ... 展开 >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom, B4 6NH Contact: Shakti Agrawal, MBBS    0044 1213338149    shakti.agrawal@bch.nhs.uk    Principal Investigator: Shakti Agrawal, MBBS          Bristol Royal Hospital for Children Recruiting Bristol, United Kingdom, BS2 8AE Contact: Andrew Mallick, FRCPCH          Principal Investigator: Andrew Mallick          Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Alasdair Parker, MA    0044 1223 245151    alasdair.parker@addenbrookes.nhs.uk    Principal Investigator: Alasdair Parker, MA          Lancashire Teaching Hospitals NHS Foundation Trust Recruiting Lancashire, United Kingdom Contact: Helen Basu       Helen.Basu@lthtr.nhs.uk    Principal Investigator: Helen Basu          Leeds Teaching Hospital Recruiting Leeds, United Kingdom, LS1 3EX Contact: Helen McCullagh, RCPCH    0044 113 243 2799    h.mccullagh@nhs.net    Principal Investigator: Helen McCullagh, RCPCH          Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom, L12 2AP Contact: Rachel Kneen, BMBS    0044 151 2525163    rachel.kneen@liverpool.ac.uk    Principal Investigator: Rachel Kneen, BMBS          Great Ormond Street Hospital Recruiting London, United Kingdom, WC1N 3JH Contact: Christin Eltze, MD Res    0044 207 405 9200 ext 5438    christin.eltze@gosh.nhs.uk    Principal Investigator: Christin Eltze, MD Res          St George's University Hospitals NHS Foundation Trust Recruiting London, United Kingdom Contact: Penny Fallon       Penny.Fallon@stgeorges.nhs.uk    Principal Investigator: Penny Fallon          Royal Manchester Children's Hospital Recruiting Manchester, United Kingdom, M13 0JE Contact: Tim Martland, RCPCH    0044 161 276 1234    timothy.martland@cmft.nhs.uk    Principal Investigator: Tim Martland, RCPCH          The Newcastle Upon Tyne Hospitals NHS Foundation Trust Recruiting Newcastle upon Tyne, United Kingdom Contact: Anita Devlin       Anita.Devlin@nuth.nhs.uk    Principal Investigator: Anita Devlin          Sheffield Children's NHS Foundation Trust Recruiting Sheffield, United Kingdom Contact: Archana Desurkar       Archana.Desurkar@sch.nhs.uk    Principal Investigator: Archana Desurkar 收起 <<
NCT01390909 - Completed - -
NCT01390909 - Completed - -

Ethosuximide/乙琥胺 参考文献

[1]Chen X, McCue HV, et al. Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression. Mol Neurodegener. 2015 Sep 29;10:51.

[2]Collins JJ, Evason K, et al. The anticonvulsant ethosuximide disrupts sensory function to extend C. elegans lifespan. PLoS Genet. 2008 Oct;4(10):e1000230.

[3]Gören MZ, Onat F. Ethosuximide: from bench to bedside. CNS Drug Rev. 2007 Summer;13(2):224-39

[4]Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9

[5]Sondossi K, Majdzadeh M, Ghaeli P, Ghahremani MH, Shafaroodi H, Paknejad B, Ostad SN. Analysis of the antiepileptic, ethosuximide impacts on neurogenesis of rat forebrain stem cells. Fundam Clin Pharmacol. 2014 Oct;28(5):512-8

[6]Fedotova IB, Perepelkina OV, Nikolaev GM, Surina NM, Poletaeva II. Effect of Ethosuximide on Audiogenic Epilepsy in Krushinsky-Molodkina Rats. Bull Exp Biol Med. 2019 Aug;167(4):464-466

Ethosuximide/乙琥胺 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

7.08mL

1.42mL

0.71mL

35.42mL

7.08mL

3.54mL

70.84mL

14.17mL

7.08mL

Ethosuximide/乙琥胺 技术信息

CAS号77-67-8
分子式C7H11NO2
分子量 141.17
SMILES Code O=C(C(C)(CC)C1)NC1=O
MDL No. MFCD00072123
别名 CI-366; Zarontin; Emeside, Ethosuccimid, Ethosuximide, Ethylmethylsuccimide, Ethymal, Zarontin.; NSC 64013
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Inert atmosphere, 2-8°C
溶解方案 请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案一
方案二

Tags: Ethosuximide | 77-67-8 | Calcium Channel | Ca2+ channels | Calcium Channel Inhibitor | Membrane Transporter/Ion Channel | Neuronal Signaling | Calcium Channel | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Ethosuximide/乙琥胺 纯度/质量文件 | Ethosuximide/乙琥胺 亚型比较 | Ethosuximide/乙琥胺 生物活性 | Ethosuximide/乙琥胺 临床数据 | Ethosuximide/乙琥胺 参考文献 | Ethosuximide/乙琥胺 实验方案 | Ethosuximide/乙琥胺 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z